

Date: 10/02/2020

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT


We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period ended **31 December 2019** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

JAYMIN SHAH & ASSOCIATES


Chartered Accountants


AHMEDABAD
M. NO. 170863

CA Mayank Sancheti

M No. 170863

Date: 10/02/2020

Place: Ahmedabad

UDIN: 20170863AAAAAH8310

Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad - 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter Ended December 31, 2019

Amount in Lacs except Per Share data

Particulars	Quarter Ended			Period Ended		Year Ended
	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 Months Ended	12 Months Ended
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
1 INCOME						
Revenue from Operations	398.481	360.766	232.440	1145.307	613.324	908.720
Other Income	6.933	2.419	0.484	12.252	4.110	16.340
Total Income	405.414	363.185	232.924	1157.559	617.434	925.060
2 EXPENSES						
(a) Cost of Material Consumed	340.665	277.961	154.100	916.356	405.256	620.620
(b) Purchase of Stock-In-Trade	0.000	0.000	0.000	2.903	0.000	6.360
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-15.963	2.058	5.010	-8.005	5.885	13.160
(d) Employee Benefit Expense	27.167	26.528	24.820	80.435	67.197	95.550
(e) Finance Cost	0.939	1.084	0.640	2.913	2.212	6.060
(f) Depreciation, Depletion and Amortisation Expense	3.893	3.580	4.666	11.693	11.967	15.590
(g) Other Expense	31.461	35.483	32.751	101.624	93.171	121.430
Total Other Expenses	31.461	35.483	32.751	101.624	93.171	121.430
Total Expenses	388.162	346.694	221.987	1107.919	585.688	878.770
3 Total Profit before Exceptional Items and Tax	17.252	16.491	10.937	49.640	31.746	46.290
4 Exceptional Items	0.000	0.000	0.000	0.000	0.000	0.000
5 Total Profit before Tax	17.252	16.491	10.937	49.640	31.746	46.290
6 Tax Expense						
7 Current Tax	4.886	3.794	3.360	12.400	12.040	11.500
8 Deferred Tax	0.000	0.000	0.000	0.000	0.000	-0.370
9 Total Tax Expenses	4.886	3.794	3.360	12.400	12.040	11.130
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000	0.000	0.000
11 Net Profit Loss for the period from continuing operations	12.366	12.697	7.577	37.240	19.706	35.160
12 Profit / (Loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
13 Tax Expenses of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
14 Net Profit / (Loss) from discontinued operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000
16 Total Profit / (Loss) for the period	12.366	12.697	7.577	37.240	19.706	35.160
17 Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000	0.000	0.000
18 Total Comprehensive Income for the Period	12.366	12.697	7.577	37.240	19.706	35.160
19 Total profit or loss attributable to						
Profit or loss, attributable to owners of parents	0.000	0.000	0.000	0.000	0.000	0.000
Total Profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
20 Total comprehensive income for the period attributable to						

Bydium approved



	Comprehensive Income for the period attributable to the owners of parents	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.030	299.030	299.030	299.030	299.030	299.030
	Face Value of Equity Share Capital	10.000	10.000	10.000	10.000	10.000	10.000
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.000	0.000	0.000	0.000	0.000	0.000
	Face Value of Debt Securities	0.000	0.000	0.000	0.000	0.000	0.000
23	Reserves Excluding Revaluation Reserves	0.000	0.000	0.000	0.000	0.000	0.000
24	Debenture Redemption Reserve	0.000	0.000	0.000	0.000	0.000	0.000
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.414	0.425	0.253	1.245	0.659	1.176
	Diluted Earnings / (Loss) per share from continuing operations	0.414	0.425	0.253	1.245	0.659	1.176
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
	Diluted Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.414	0.425	0.253	1.245	0.659	1.176
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.414	0.425	0.253	1.245	0.659	1.176
26	Debt Equity Ratio*	0.000	0.000	0.000	0.000	0.000	0.000
27	Debt Service Coverage Ratio*	0.000	0.000	0.000	0.000	0.000	0.000
28	Interest Service Coverage Ratio*	0.000	0.000	0.000	0.000	0.000	0.000

* The Company has no long term debt as on date

NOTES

- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 11, 2020.
- The Limited Review of the results has been completed by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
- The financial results for the quarter and half year ended 30th September, 2018 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
- Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
- Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL
MANAGING DIRECTOR

Place **Ahmedabad**
Date **11-Feb-2020**

DIN: 01031687